Showing results (431-440 of 514) with videos related to

Sort By:
Pageof 52
Journal of Medicinal Chemistry|January 5, 2002
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitorsCarol K Wada, James H Holms, Michael L Curtin, et al.
ACS Medicinal Chemistry Letters|July 16, 2021
Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 InhibitorsYunsong Tong, Alan S Florjancic, Rick F Clark, et al.
The Journal of Allergy and Clinical Immunology|February 6, 2013
Defective actin accumulation impairs human natural killer cell function in patients with dedicator of cytokinesis 8 deficiencyMelissa C Mizesko, Pinaki P Banerjee, Linda Monaco-Shawver, et al.
British Journal of Haematology|July 21, 2018
Low incidence of symptomatic osteonecrosis after allogeneic HSCT in children with high-risk or relapsed ALL - results of the ALL-SCT 2003 trialMichaela Kuhlen, Peter Bader, Martin Sauer, et al.
Bioorganic & Medicinal Chemistry Letters|April 3, 2012
Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase familiesMichael L Curtin, Robin R Frey, H Robin Heyman, et al.
The Journal of Allergy and Clinical Immunology|June 21, 2017
Mechanisms of genotype-phenotype correlation in autosomal dominant anhidrotic ectodermal dysplasia with immune deficiencyDaniel Petersheim, Michel J Massaad, Saetbyul Lee, et al.
Journal of Medicinal Chemistry|April 24, 2020
Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second BromodomainGeorge S Sheppard, Le Wang, Steven D Fidanze, et al.
Journal of Medicinal Chemistry|January 23, 1998
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonistsM L Curtin, S K Davidsen, H R Heyman, et al.
Clinical Immunology (Orlando, Fla.)|February 19, 2019
Increased proportions of γδ T lymphocytes in atypical SCID associate with disease manifestationsInga Tometten, Kerstin Felgentreff, Manfred Hönig, et al.
Blood Advances|January 8, 2025
Extended clinical phenotypes and treatment modalities in 32 JAGN1-deficient patients: a multicenter study by ESID and EBMT IEWPJulia Fekadu-Siebald, Emilia Salzmann-Manrique, Jan Robert Heusel, et al.
Pageof 52